Cantex Pharmaceuticals’ CX-01 receives FDA fast track designation in acute myeloid leukemia
Cantex Pharmaceuticals, a Florida-based biotechnology company, has achieved a significant milestone by securing Fast Track designation from the US Food and Drug Administration (FDA) for its innovative acute myeloid leukemia (AML) drug, CX-01. This designation is specifically for the treatment of patients over 60 years old undergoing induction therapy for newly diagnosed AML. CX-01 is […]